Cargando…
Expression of gain-of-function CFTR in cystic fibrosis airway cells restores epithelial function better than wild-type or codon-optimized CFTR
Class Ia/b cystic fibrosis transmembrane regulator (CFTR) variants cause severe lung disease in 10% of cystic fibrosis (CF) patients and are untreatable with small-molecule pharmaceuticals. Genetic replacement of CFTR offers a cure, but its effectiveness is limited in vivo. We hypothesized that enha...
Autores principales: | Woodall, Maximillian, Tarran, Robert, Lee, Rhianna, Anfishi, Hafssa, Prins, Stella, Counsell, John, Vergani, Paola, Hart, Stephen, Baines, Deborah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494266/ https://www.ncbi.nlm.nih.gov/pubmed/37701179 http://dx.doi.org/10.1016/j.omtm.2023.08.006 |
Ejemplares similares
-
Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation
por: Stefano, Daniela De, et al.
Publicado: (2014) -
Fluorescence assay for simultaneous quantification of CFTR ion-channel function and plasma membrane proximity
por: Prins, Stella, et al.
Publicado: (2021) -
Targeted therapies to improve CFTR function in cystic fibrosis
por: Brodlie, Malcolm, et al.
Publicado: (2015) -
Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators
por: Pranke, Iwona M., et al.
Publicado: (2017) -
Molecular and functional correction of a deep intronic splicing mutation in CFTR by CRISPR-Cas9 gene editing
por: Walker, Amy J., et al.
Publicado: (2023)